Lumos Diagnostics Expands FebriDx Network Across 430 US Urgent Care Sites

• Top 100 US urgent care group begins network rollout at 30+ sites
• Three tier 1 groups with 230+ sites in clinical and economic validation
• Four accounts represent 2.6 million acute respiratory infection presentations annually
• Lumos uses a four-stage framework to track commercial progress
• FebriDx sales flow through exclusive Phase Scientific distributor

Rapid Expansion in US Urgent Care Networks

Lumos Diagnostics (ASX:LDX) is making tangible strides in commercialising its FebriDx rapid diagnostic test across the United States. A leading regional urgent care group within the top 100 US providers has swiftly moved from discussions to deploying FebriDx across more than 30 sites. This network rollout represents an estimated annual opportunity of around 200,000 acute respiratory infection (ARI) presentations.

The significance of this move is amplified by the fact that nearly 60% of the top 100 urgent care groups are owned by or affiliated with large health systems, underscoring the strategic value of such partnerships for Lumos. The health system behind this rollout operates over 200 sites, spanning urgent care centres, hospitals, and ambulatory clinics, positioning FebriDx for potential expansion beyond urgent care into broader clinical pathways.

Validation Underway in Three Tier 1 Urgent Care Groups

Beyond the initial rollout, Lumos is advancing clinical and economic validation with three additional high-profile urgent care groups ranked within the top 10, 25, and 30 nationally. Collectively, these accounts cover more than 230 sites and are pivotal to Lumos’ strategy of securing multi-site adoption through successful validation pilots.

CEO Doug Ward highlighted that these four accounts combined represent over 430 potential sites and a minimum internal estimate of 2.6 million ARI presentations annually. This scale illustrates the sizeable addressable market Lumos is targeting as these engagements mature, potentially driving meaningful growth in FebriDx utilisation.

A Structured Framework Guides Commercial Progress

Lumos employs a four-stage commercial framework to track and communicate the advancement of priority accounts. These stages include qualified opportunities, clinical and economic validation, network rollout, and standardised adoption where FebriDx becomes embedded in routine clinical protocols. This approach mirrors the pathway established with WellStreet Urgent Care, where initial pilots expanded to 44 sites and set the stage for nationwide deployment across 165 locations.

All FebriDx sales in the US flow through Lumos’ exclusive distribution agreement with Phase Scientific, with revenue recognised upon shipment to the distributor. This arrangement supports Lumos’ scalable commercial model as it deepens penetration in urgent care networks.

Maintaining Consistency with Prior Communications

This update builds on Lumos’ June 2026 investor presentation, providing more granular account-level detail without altering previously disclosed commercial metrics. The company plans to continue refining its progress reporting, helping investors better assess how individual priority accounts evolve from initial engagement to standardised adoption.

While the announcement does not disclose specific financial impacts or timelines for full adoption, it signals growing clinical confidence and strategic traction within large US health system-owned urgent care networks, a critical channel for Lumos’ US commercial ambitions.

Bottom Line?

Lumos is converting its US urgent care pipeline into tangible deployments, but the path from validation to standardised adoption across thousands of sites remains the key hurdle ahead.

Questions in the middle?

• How quickly will the three tier 1 urgent care groups complete clinical and economic validation?
• What revenue growth can Lumos expect as FebriDx moves from pilot to standardised adoption?
• Will Lumos expand beyond urgent care into broader health system settings using FebriDx?